| |
| |
|
| Insider
Information: |
Shanmugam Muthusamy |
| Relationship: |
HEAD OF R&D, COO-NOVIT... |
| City: |
Baudette |
| State: |
MN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
68,652 |
|
|
Indirect Shares
|
737,620 |
|
|
| Direct
Value |
$4,616,847 |
|
|
|
Indirect Value
|
$49,604,945 |
|
|
| Total
Shares |
806,272 |
|
|
| Total
Value |
$54,221,792 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
ANI Pharmaceuticals Inc |
ANIP |
HEAD OF R&D, COO-NOVIT... |
2024-05-20 |
68,652 |
2024-05-20 |
737,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
58 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2024-01-16 |
4 |
AS |
$55.63 |
$278,150 |
I/I |
(5,000) |
927,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-12-19 |
4 |
AS |
$52.65 |
$1,316,250 |
I/I |
(25,000) |
932,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-12-18 |
4 |
AS |
$52.44 |
$683,083 |
I/I |
(13,026) |
957,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-12-15 |
4 |
AS |
$52.44 |
$627,917 |
I/I |
(11,974) |
970,646 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-17 |
4 |
AS |
$51.00 |
$663,000 |
I/I |
(13,000) |
982,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-16 |
4/A |
AS |
$51.66 |
$333,104 |
I/I |
(6,448) |
995,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-16 |
4 |
AS |
$51.66 |
$333,104 |
I/I |
(6,448) |
996,430 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-15 |
4/A |
AS |
$53.64 |
$410,185 |
I/I |
(7,647) |
1,002,068 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-15 |
4 |
AS |
$53.64 |
$410,185 |
I/I |
(7,647) |
1,002,878 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-14 |
4/A |
AS |
$53.17 |
$1,217,859 |
I/I |
(22,905) |
1,009,715 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-11-14 |
4 |
AS |
$53.17 |
$1,174,791 |
I/I |
(22,095) |
1,010,525 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-19 |
4 |
AS |
$57.06 |
$570,600 |
I/I |
(10,000) |
1,032,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-18 |
4 |
AS |
$57.78 |
$360,663 |
I/I |
(6,242) |
1,042,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-17 |
4 |
AS |
$58.53 |
$512,606 |
I/I |
(8,758) |
1,048,862 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-16 |
4 |
AS |
$58.31 |
$761,704 |
I/I |
(13,063) |
1,057,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-13 |
4 |
AS |
$57.58 |
$687,332 |
I/I |
(11,937) |
1,070,683 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-19 |
4 |
AS |
$61.23 |
$1,551,140 |
I/I |
(25,333) |
1,082,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-18 |
4 |
AS |
$61.64 |
$519,317 |
I/I |
(8,425) |
1,107,953 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-15 |
4 |
AS |
$62.81 |
$1,020,160 |
I/I |
(16,242) |
1,116,378 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-29 |
4 |
S |
$63.37 |
$1,584,250 |
I/I |
(25,000) |
1,132,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-28 |
4 |
S |
$63.06 |
$1,576,500 |
I/I |
(25,000) |
1,157,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-15 |
4 |
AS |
$61.60 |
$1,361,976 |
I/I |
(22,110) |
1,182,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-14 |
4 |
AS |
$61.15 |
$1,705,474 |
I/I |
(27,890) |
1,204,730 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-21 |
4 |
AS |
$52.56 |
$604,440 |
I/I |
(11,500) |
1,232,620 |
0 |
- |
|
| ANIP |
ANI Pharmaceuticals Inc |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-07-20 |
4 |
AS |
$51.52 |
$309,120 |
I/I |
(6,000) |
1,244,120 |
0 |
- |
|
58 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
